Credit: Shutterstock photoHealthcare shares were fairly flat in pre-market trade on Friday.
In healthcare stocks news, Aratana Therapeutics ( PETX ) late Thursday announced an agreement to gain exclusive rights to sell and develop a treatment for pain and inflammation of osteoarthritis in dogs based on Vet-Stem's allogeneic stem cell therapy technology. If approved, Vet-Stem's technology will be the first FDA-regulated, "off the shelf" regenerative cell therapy for the treatment of osteoarthritis in dogs.
And, TG Therapeutics, Inc. ( TGTX ), a clinical-stage biopharmaceutical company, shares were down about 5% after it announced preliminary clinical results from its ongoing Phase 2 study of TG-1101, the company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib,
The oral BTK inhibitor from Pharmacyclics/Janssen. Data from the Phase 2 study is being presented during the 19th Annual European Hematology Association meeting being held in Milan, Italy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
